H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This is 3-arm, multicenter study that will be conducted through the Pacific Pediatric
Neuro-oncology Consortium (PNOC).
This study will assess the safety and immune activity of a synthetic peptide vaccine specific
for the H3.3.K27M epitope given in combination with poly-ICLC and the H3.3.K27M epitope given
in combination with poly-ICLC and the PD-1 inhibitor, nivolumab, in HLA-A2 (02:01)+ children
with newly diagnosed DIPG or other midline gliomas that are positive for H3.3K27M.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sabine Mueller, MD, PhD
Collaborators:
Bristol-Myers Squibb Pacific Pediatric Neuro-Oncology Consortium The V Foundation for Cancer Research